Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan Names Gary E. Sphar Vice President-Corporate Controller
Mylan Names Gary E. Sphar Vice President-Corporate Controller PITTSBURGH, Jul 24, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that Gary E. Sphar was named Vice President-Corporate Controller. Mr. Sphar will be responsible for accounting policies and functions,
View HTML
Toggle Summary Mylan Announces Succession Plan
Mylan Announces Succession Plan PITTSBURGH, Jul 18, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) today announced that effective September 1, 2002, Robert J. Coury, 41, will become Chief Executive Officer of Mylan Laboratories and Louis J.
View HTML
Toggle Summary Mylan Announces First Quarter Fiscal 2003 Earnings Release Date and Conference Call
Mylan Announces First Quarter Fiscal 2003 Earnings Release Date and Conference Call PITTSBURGH, Jul 17, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that it will release its first quarter fiscal 2003 financial results before the market opens on Thursday, July 25, 2002.
View HTML
Toggle Summary Mylan Receives Approval for Nizatidine Capsules
Mylan Receives Approval for Nizatidine Capsules PITTSBURGH, Jul 9, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Nizatidine Capsules, 150 mg and 300 mg.
View HTML
Toggle Summary Mylan Receives Approval for Lisinopril and Lisinopril/HCTZ
Mylan Receives Approval for Lisinopril and Lisinopril/HCTZ PITTSBURGH, Jul 2, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that the U.S. Food and Drug Administration (FDA) has approved its Abbreviated New Drug Applications (ANDAs) for Lisinopril Tablets in 2.5 mg, 5
View HTML
Toggle Summary Mylan Receives Approval for Tramadol Hydrochloride Tablets
Mylan Receives Approval for Tramadol Hydrochloride Tablets PITTSBURGH, Jun 21, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE:MYL) announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Tramadol Hydrochloride Tablets, 50 mg.
View HTML
Toggle Summary Mylan Declares Regular Quarterly Cash Dividend
Mylan Declares Regular Quarterly Cash Dividend PITTSBURGH--(BUSINESS WIRE)--June 17, 2002--Mylan Laboratories Inc. (NYSE:MYL) announced today that the regular quarterly cash dividend of four cents per share will be paid on July 15, 2002 to shareholders of record June 30, 2002.
View HTML
Toggle Summary Mylan Receives Approval on Levothyroxine Sodium Tablets
Mylan Receives Approval on Levothyroxine Sodium Tablets PITTSBURGH, Jun 11, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. announced today that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for Levothyroxine Sodium Tablets USP, 0.025 mg, 0.05 mg,
View HTML
Toggle Summary Mylan Signs Licensing Agreement With 3M Pharmaceuticals
Mylan Signs Licensing Agreement With 3M Pharmaceuticals PITTSBURGH, Jun 7, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it has reached an agreement with 3M Pharmaceuticals for an exclusive supply and distribution agreement to sell Flecainide Acetate Tablets in
View HTML
Toggle Summary Mylan Reports Record Revenues and Earnings For The Fourth Quarter and Fiscal 2002
Mylan Reports Record Revenues and Earnings For The Fourth Quarter and Fiscal 2002 PITTSBURGH, May 8, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc.(NYSE: MYL) - Financial Highlights: - Net revenues increased 30% to exceed $1.1 billion for the fiscal year and 14% to $282.6 million for the quarter.
View HTML